Trial Profile

A Randomized Phase II Study of Sequencing Abiraterone Acetate and Enzalutamide in Metastatic Castration-Resistant Prostate Cancer

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 28 Oct 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

13 Sep 2021 Results assessing the impact of treatment with abiraterone or enzalutamide as well as HSD3B1 gene mutation on steroid hormones, quantified by mass spectrometry (MS) in patients with CRPCpresented at the 116th Annual Meeting of the American Urological Association
03 Jun 2021 Results assessing acquired genomic contributors to cross-resistance in metastatic castration-resistant prostate cancer, published in the Clinical Cancer Research.
06 Aug 2020 Status changed from active, no longer recruiting to completed.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com